Zobrazeno 1 - 10
of 229
pro vyhledávání: '"Klaus Pfizenmaier"'
Autor:
Natalia Ortí-Casañ, Ate S. Boerema, Karina Köpke, Amber Ebskamp, Jan Keijser, Yuequ Zhang, Tingting Chen, Amalia M. Dolga, Kerensa Broersen, Roman Fischer, Klaus Pfizenmaier, Roland E. Kontermann, Ulrich L. M. Eisel
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Tumor necrosis factor alpha (TNF-α) and its key role in modulating immune responses has been widely recognized as a therapeutic target for inflammatory and neurodegenerative diseases. Even though inhibition of TNF-α is beneficial for the t
Externí odkaz:
https://doaj.org/article/c98638b7b125423496722b05327a5864
Autor:
Kayla L. Nguyen, Ishaan J. Bhatt, Shruti Gupta, Nazaf Showkat, Kathryn A. Swanson, Roman Fischer, Roland E. Kontermann, Klaus Pfizenmaier, Valerie Bracchi-Ricard, John R. Bethea
Publikováno v:
Brain Research Bulletin, Vol 207, Iss , Pp 110885- (2024)
Multiple sclerosis (MS), a demyelinating autoimmune disease of the central nervous system (CNS), predominately affects females compared to males. Tumor necrosis factor (TNF), a pro-inflammatory cytokine, signaling through TNF receptor 1 contributes t
Externí odkaz:
https://doaj.org/article/667057d00d2a42bdb40ed215236bb75d
Autor:
Valentina Pegoretti, Jan Bauer, Roman Fischer, Iskra Paro, Wanda Douwenga, Roland E. Kontermann, Klaus Pfizenmaier, Evelien Houben, Bieke Broux, Niels Hellings, Wia Baron, Jon D. Laman, Ulrich L. M. Eisel
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-13 (2023)
Abstract TNF signaling is an essential regulator of cellular homeostasis. Through its two receptors TNFR1 and TNFR2, soluble versus membrane-bound TNF enable cell death or survival in a variety of cell types. TNF-TNFRs signaling orchestrates importan
Externí odkaz:
https://doaj.org/article/5841bf7052c54683ab34c56469546a89
Autor:
Timon Fiedler, Richard Fairless, Kira Pichi, Roman Fischer, Fabian Richter, Roland E. Kontermann, Klaus Pfizenmaier, Ricarda Diem, Sarah K. Williams
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-13 (2023)
Abstract Background Tumour necrosis factor (TNF) is a pleiotropic cytokine and master regulator of the immune system. It acts through two receptors resulting in often opposing biological effects, which may explain the lack of therapeutic potential ob
Externí odkaz:
https://doaj.org/article/419220a7d4354d2c8e22cb1683c5790a
Autor:
Fabian Richter, Sarah K. Williams, Katharina John, Carina Huber, Camille Vaslin, Henri Zanker, Richard Fairless, Kira Pichi, Silke Marhenke, Arndt Vogel, Marie-Ann Dhaen, Stefanie Herrmann, Andreas Herrmann, Klaus Pfizenmaier, Heike Bantel, Ricarda Diem, Roland E. Kontermann, Roman Fischer
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Therapeutics that block tumor necrosis factor (TNF), and thus activation of TNF receptor 1 (TNFR1) and TNFR2, are clinically used to treat inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, TNFR1 an
Externí odkaz:
https://doaj.org/article/1a907a62ef2147babfb0eca1aa339f4b
Autor:
Franziska Hartung, Thomas Krüwel, Xiaoyi Shi, Klaus Pfizenmaier, Roland Kontermann, Patrick Chames, Frauke Alves, Luis A. Pardo
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Antibody-based therapies hold promise for a safe and efficient treatment of cancer. The identification of target tumor cells through a specific antigen enriched on their surface and the subsequent delivery of the therapeutic agent only to those cells
Externí odkaz:
https://doaj.org/article/8a17bf723c6c4c479977eba27d884887
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-inflammatory effects, drugs that neutralize TNF were developed and are clinically used to treat inflammatory and autoimmune diseases, such as rheumatoid arthritis
Externí odkaz:
https://doaj.org/article/6c5fc9369bc544ca85760cf652c558ad
Autor:
Sarah K. Williams, Richard Fairless, Olaf Maier, Patricia C. Liermann, Kira Pichi, Roman Fischer, Ulrich L. M. Eisel, Roland Kontermann, Andreas Herrmann, Babette Weksler, Nacho Romero, Pierre-Olivier Couraud, Klaus Pfizenmaier, Ricarda Diem
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-14 (2018)
Abstract Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such as multiple sclerosis. T
Externí odkaz:
https://doaj.org/article/1d5fda7e325a49d7ac87de90f8d6525b
Autor:
Tanja Padutsch, Maksim Sendetski, Carina Huber, Nathalie Peters, Klaus Pfizenmaier, John R. Bethea, Roland E. Kontermann, Roman Fischer
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Autoimmune diseases are caused by uncontrolled endogenous immune responses against healthy cells. They may develop due to an impaired function of regulatory T cells (Tregs), which normally suppress self-specific effector immune cells. Interleukin 2 (
Externí odkaz:
https://doaj.org/article/49fe5861275a40c683d881ca1fc38305
Autor:
Roman Fischer, Jessica Marsal, Cristiano Guttà, Stephan A. Eisler, Nathalie Peters, John R. Bethea, Klaus Pfizenmaier, Roland E. Kontermann
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract Tumor necrosis factor receptor 2 (TNFR2) is known to mediate immune suppression and tissue regeneration. Interestingly, the transmembrane form of tumor necrosis factor (tmTNF) is necessary to robustly activate TNFR2. To characterize the stoi
Externí odkaz:
https://doaj.org/article/5426e79d6acc4127b9912c15e577861b